Literature DB >> 20803306

Cytotoxic effects of statins and thiazolidinediones on meningioma cells.

Sonja Gehring1, Jorge Humberto Tapia-Pérez, Elmar Kirches, Raimund Firsching, Gerburg Keilhoff, Thomas Schneider, Christian Mawrin.   

Abstract

Statins are inhibitors of the cholesterol synthesis pathway with pleiotropic effects, while thiazolidinediones (TDZ) are peroxisomal proliferator activator receptor γ (PPAR-γ) agonists with potent proapoptotic activity. For both groups of substances a cytotoxic effect against several human tumors is presumed. Direct comparison of several statins and TDZ has not been performed on meningioma cells until now. We compared the antiproliferative/cytotoxic effect of five statins, two TDZ, and their combinations on various human meningioma cell lines and nontumorous cells using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, cell cycle analysis, and caspase-3 assay. Simvastatin (SMV) and its combination with the TDZ pioglitazone (PGZ) turned out to be the most effective treatment. After 96 h the 50% inhibition concentration (IC(50)) of SMV in MTT assays for two more sensitive meningioma cell lines (one benign and one malignant) was below 0.9 μM, while the IC(50) was 2.8 μM or higher for two other meningioma lines. Fluorescence-activated cell sorting (FACS) analysis suggested that MTT results mostly represented cytotoxic rather than antiproliferative effects. Strong caspase-3 induction suggested participation of intrinsic apoptosis in meningioma cell death. In contrast, SMV showed no substantial effects on fibroblasts and astrocytes. Addition of 40 μM PGZ significantly decreased the fraction of clonogenic cells in soft-agar assays, as compared with 2.8 μM SMV alone. Taken together, SMV showed a significant cytotoxic effect against human meningioma cells, which was moderately enhanced by PGZ.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20803306     DOI: 10.1007/s11060-010-0351-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  38 in total

1.  Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone.

Authors:  Chih-Jung Yao; Gi-Ming Lai; Chin-Feng Chan; Ann-Lii Cheng; Ya-Yu Yang; Shuang-En Chuang
Journal:  Int J Cancer       Date:  2006-02-01       Impact factor: 7.396

2.  Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas.

Authors:  Christian Mawrin; Tina Sasse; Elmar Kirches; Siegfried Kropf; Thomas Schneider; Christoph Grimm; Claudia Pambor; Christian K Vorwerk; Raimund Firsching; Uwe Lendeckel; Knut Dietzmann
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

3.  Lovastatin induces a pronounced differentiation response in acute myeloid leukemias.

Authors:  J Dimitroulakos; S Thai; G H Wasfy; D W Hedley; M D Minden; L Z Penn
Journal:  Leuk Lymphoma       Date:  2000-12

4.  Role of hydrodynamic processes in the pathogenesis of peritumoral brain edema in meningiomas.

Authors:  M Bitzer; T Nägele; B Geist-Barth; U Klose; E Grönewäller; M Morgalla; E Heiss; K Voigt
Journal:  J Neurosurg       Date:  2000-10       Impact factor: 5.115

5.  Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.

Authors:  U M Schrell; M G Rittig; M Anders; U H Koch; R Marschalek; F Kiesewetter; R Fahlbusch
Journal:  J Neurosurg       Date:  1997-05       Impact factor: 5.115

6.  3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity.

Authors:  Anna Zacco; James Togo; Katherine Spence; Amanda Ellis; Darlene Lloyd; Steve Furlong; Timothy Piser
Journal:  J Neurosci       Date:  2003-12-03       Impact factor: 6.167

7.  Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.

Authors:  A Thibault; D Samid; A C Tompkins; W D Figg; M R Cooper; R J Hohl; J Trepel; B Liang; N Patronas; D J Venzon; E Reed; C E Myers
Journal:  Clin Cancer Res       Date:  1996-03       Impact factor: 12.531

8.  Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma.

Authors:  José M Pérez-Ortiz; Pedro Tranque; Cecilia F Vaquero; Beatriz Domingo; Francisca Molina; Soledad Calvo; Joaquín Jordán; Valentín Ceña; Juan Llopis
Journal:  J Biol Chem       Date:  2003-12-29       Impact factor: 5.157

9.  Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.

Authors:  Michel Kalamarides; Anat O Stemmer-Rachamimov; Masaya Takahashi; Zhi-Yan Han; Fabrice Chareyre; Michiko Niwa-Kawakita; Peter M Black; Rona S Carroll; Marco Giovannini
Journal:  Brain Pathol       Date:  2007-10-09       Impact factor: 6.508

10.  Lovastatin sensitized human glioblastoma cells to TRAIL-induced apoptosis.

Authors:  David Y L Chan; George G Chen; Wai S Poon; Pi C Liu
Journal:  J Neurooncol       Date:  2007-10-11       Impact factor: 4.130

View more
  5 in total

Review 1.  Chemotherapy and chemoprevention by thiazolidinediones.

Authors:  Eleonore Fröhlich; Richard Wahl
Journal:  Biomed Res Int       Date:  2015-03-19       Impact factor: 3.411

2.  Cannabis Therapeutics and the Future of Neurology.

Authors:  Ethan B Russo
Journal:  Front Integr Neurosci       Date:  2018-10-18

Review 3.  Repurposing of Anticancer Stem Cell Drugs in Brain Tumors.

Authors:  Hisham F Bahmad; Darine Daher; Abed A Aljamal; Mohamad K Elajami; Kei Shing Oh; Juan Carlos Alvarez Moreno; Ruben Delgado; Richard Suarez; Ana Zaldivar; Roshanak Azimi; Amilcar Castellano; Robert Sackstein; Robert J Poppiti
Journal:  J Histochem Cytochem       Date:  2021-06-24       Impact factor: 2.479

4.  The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination.

Authors:  Graham Skelhorne-Gross; Christopher J B Nicol
Journal:  PPAR Res       Date:  2012-07-02       Impact factor: 4.964

5.  KLF4K409Q-mutated meningiomas show enhanced hypoxia signaling and respond to mTORC1 inhibitor treatment.

Authors:  Niklas von Spreckelsen; Natalie Waldt; Rebecca Poetschke; Christoph Kesseler; Hildegard Dohmen; Hui-Ke Jiao; Attila Nemeth; Stefan Schob; Cordula Scherlach; Ibrahim Erol Sandalcioglu; Martina Deckert; Frank Angenstein; Boris Krischek; Pantelis Stavrinou; Marco Timmer; Marc Remke; Elmar Kirches; Roland Goldbrunner; E Antonio Chiocca; Stefan Huettelmaier; Till Acker; Christian Mawrin
Journal:  Acta Neuropathol Commun       Date:  2020-04-03       Impact factor: 7.801

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.